Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials

• Published in: Journal of headache and pain Vol. 22; no. 1; pp. 48 - 10
• Main Authors: Jedynak, Jakub, Eross, Eric, Gendolla, Astrid, Rettiganti, Mallikarjuna, Stauffer, Virginia L.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.12.2021; Springer Nature B.V; BMC
• Subjects: Antibodies, Monoclonal, Humanized; Clinical trials; Dosage; Drug therapy; Episodic migraine; Headache; Headaches; Humans; Internal Medicine; Medicine; Medicine & Public Health; MIDAS; Migraine; Migraine Disorders - drug therapy; Migraine frequency; Monoclonal antibodies; MSQ-RFR; Neurology; Pain Medicine; Patients; Placebos; QoL; Quality of Life; Randomized Controlled Trials as Topic; Remission; Research Article; Sustained improvement; Migraine frequency; MSQ-RFR; Sustained improvement; Episodic migraine; MIDAS; QoL

Background Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acute treatment overuse versus those with low-frequency...